Why a twice‑yearly injection might prove to be a good shot Lenacapavir is a first-in-class HIV drug that works by targeting ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Rwanda is among the countries interested in Lenacapavir, a newly approved, long-acting preventive injection, though its cost is seemingly out of reach for many developing countries. Manufactured by US ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Although Uganda participated in a groundbreaking trial for Lenacapavir—an injectable drug proven effective in preventing ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...